THARIMMUNE INC (THAR)

US4327053090 - Common Stock

2.1  -0.08 (-3.67%)

Fundamental Rating

2

Taking everything into account, THAR scores 2 out of 10 in our fundamental rating. THAR was compared to 568 industry peers in the Biotechnology industry. While THAR seems to be doing ok healthwise, there are quite some concerns on its profitability. THAR does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year THAR has reported negative net income.
THAR had a negative operating cash flow in the past year.
THAR had negative earnings in each of the past 5 years.
In the past 5 years THAR always reported negative operating cash flow.

1.2 Ratios

THAR has a worse Return On Assets (-206.63%) than 91.15% of its industry peers.
With a Return On Equity value of -359.59%, THAR is not doing good in the industry: 76.81% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -206.63%
ROE -359.59%
ROIC N/A
ROA(3y)-188.86%
ROA(5y)-1021.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for THAR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for THAR has been increased compared to 1 year ago.
There is no outstanding debt for THAR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

THAR has an Altman-Z score of -14.24. This is a bad value and indicates that THAR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -14.24, THAR is doing worse than 81.06% of the companies in the same industry.
There is no outstanding debt for THAR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.24
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

THAR has a Current Ratio of 2.35. This indicates that THAR is financially healthy and has no problem in meeting its short term obligations.
THAR has a worse Current ratio (2.35) than 72.04% of its industry peers.
A Quick Ratio of 2.35 indicates that THAR has no problem at all paying its short term obligations.
The Quick ratio of THAR (2.35) is worse than 70.80% of its industry peers.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 2.35

More info and screens

1

3. Growth

3.1 Past

THAR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.41%, which is quite impressive.
EPS 1Y (TTM)92.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 25.98% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.91%
EPS Next 2Y41.4%
EPS Next 3Y25.98%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

THAR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for THAR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as THAR's earnings are expected to grow with 25.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.4%
EPS Next 3Y25.98%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for THAR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THARIMMUNE INC

NASDAQ:THAR (12/18/2024, 8:00:01 PM)

2.1

-0.08 (-3.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.13M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -206.63%
ROE -359.59%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.35
Quick Ratio 2.35
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)92.41%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y99.91%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y